The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force
Abstract
Importance: Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy. Objective: To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force. Data Sources: Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991), and Cochrane Database of Systematic Reviews (from 2005) to June 2016. Study Selection: Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events. Data Extraction and Synthesis: One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Data were pooled using random-effects meta-analysis. Main Outcomes and Measures: All-cause mortality, CVD-related morbidity or mortality, and harms. Results: Nineteen trials (n = 71 344 participants [range, 95-17 802]; mean age, 51-66 years) compared statins vs placebo or no statin. Statin therapy was associated with decreased risk of all-cause mortality (risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]; I2 = 0%; absolute risk difference [ARD], -0.40% [95% CI, -0.64% to -0.17%]), cardiovascular mortality (RR, 0.69 [95% CI, 0.54 to 0.88]; I2 = 54%; ARD, -0.43% [95% CI, -0.75% to -0.11%]), stroke (RR, 0.71 [95% CI, 0.62 to 0.82]; I2 = 0; ARD, -0.38% [95% CI, -0.53% to -0.23%]), myocardial infarction (RR, 0.64 [95% CI, 0.57 to 0.71]; I2 = 0%; ARD, -0.81% [95% CI, -1.19 to -0.43%]), and composite cardiovascular outcomes (RR, 0.70 [95% CI, 0.63 to 0.78]; I2 = 36%; ARD, -1.39% [95% CI, -1.79 to -0.99%]). Relative benefits appeared consistent in demographic and clinical subgroups, including populations without marked hyperlipidemia (total cholesterol level <200 mg/dL); absolute benefits were higher in subgroups at higher baseline risk. Statins were not associated with increased risk of serious adverse events (RR, 0.99 [95% CI, 0.94 to 1.04]), myalgias (RR, 0.96 [95% CI, 0.79 to 1.16]), or liver-related harms (RR, 1.10 [95% CI, 0.90 to 1.35]). In pooled analysis, statins were not associated with increased risk of diabetes (RR, 1.05 [95% CI, 0.91 to 1.20]), although statistical heterogeneity was present (I2 = 52%), and 1 trial found high-intensity statins associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). No trial directly compared titrated vs fixed-dose statins, and there were no clear differences based on statin intensity. Conclusions and Relevance: In adults at increased CVD risk but without prior CVD events, statin therapy was associated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater absolute benefits in patients at greater baseline risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Tarver, T. (2014) · Journal of Consumer Health On the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,605
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · eScholarship (California Digital Library) · Cited by 2,601
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Lerner, D. J., & Kannel, W. B. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90155-9 · Cited by 1,725
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Morrison, A., Polisena, J., Husereau, D., Moulton, K., Clark, M., Fiander, M., Mierzwinski-Urban, M., Clifford, T., Hutton, B., & Rabb, D. (2012) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462312000086 · Cited by 1,257
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 867
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Chan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815
Ridker, P. M., Rifai, N., & Clearfield, M. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00460-3 · Cited by 760
Crouse, J. R., Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O’Leary, D. H., Grobbee, D. E., Bots, M. L., & METEOR Study Group, F. T. (2007) · JAMA · doi:10.1001/jama.297.12.1344 · Cited by 708
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Salonen, R., Nyyssönen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.-S., & Salonen, J. T. (1995) · Circulation · doi:10.1161/01.cir.92.7.1758 · Cited by 540
Sever, P. S., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 524
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., van Boven, A. J., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 523
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522
DeFilippis, A. P., Young, R., Carrubba, C. J., McEvoy, J. W., Budoff, M. J., Blumenthal, R. S., Kronmal, R. A., McClelland, R. L., Nasir, K., & Blaha, M. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1281 · Cited by 515
Statins: new American guidelines for prevention of cardiovascular disease
Ridker, P. M., & Cook, N. R. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62388-0 · Cited by 481
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change
Cornell, J. E., Mulrow, C. D., Localio, R., Stack, C. B., Meibohm, A. R., Guallar, E., & Goodman, S. N. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2886 · Cited by 453
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Culver, A. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.625 · Cited by 444
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439
An Overview Of Cardiovascular Disease Burden In The United States
Mensah, G. A., & Brown, D. W. (2007) · Health Affairs · doi:10.1377/hlthaff.26.1.38 · Cited by 429
Helfand, M., Buckley, D. I., Freeman, M., Fu, R., Rogers, K., Fleming, C., & Humphrey, L. L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-7-200910060-00010 · Cited by 382
Kavousi, M., Leening, M. J. G., Nanchen, D., Greenland, P., Graham, I. M., Steyerberg, E. W., Ikram, M. A., Stricker, B. H., Hofman, A., & Franco, O. H. (2014) · JAMA · doi:10.1001/jama.2014.2632 · Cited by 351
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 309
Mercuri, M., Bond, M. G., Sirtori, C. R., Veglia, F., Crepaldi, G., Saverio Feruglio, F., Descovich, G., Ricci, G., Rubba, P., Mancini, M., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00333-6 · Cited by 253
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Muldoon, M. F., Ryan, C. M., Sereika, S. M., Flory, J. D., & Manuck, S. B. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.07.041 · Cited by 248
Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J., & Francis, D. P. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314525531 · Cited by 214
Pham, B., Klassen, T. P., Lawson, M. L., & Moher, D. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.08.021 · Cited by 206
Macedo, A. F., Taylor, F. C., Casas, J. P., Adler, A., Prieto-Merino, D., & Ebrahim, S. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-51 · Cited by 184
Dormuth, C. R., Filion, K. B., Paterson, J. M., James, M. T., Teare, G. F., Raymond, C. B., Rahme, E., Tamim, H., Lipscombe, L., & for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators (2014) · BMJ · doi:10.1136/bmj.g3244 · Cited by 180
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
Tonelli, M. A., Lloyd, A., Clement, F., Conly, J. M., Husereau, D., Hemmelgarn, B. R., Klarenbach, S. W., McAlister, F. A., Wiebe, N., Manns, B., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.101280 · Cited by 173
Bonovas, S., Filioussi, K., Flordellis, C. S., & Sitaras, N. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8936 · Cited by 141
Statins and the risk of new-onset diabetes: a review of recent evidence
Preiss, D., & Sattar, N. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 125
Anderssen, S. A., Hjelstuen, A., Hjermann, I., Bjerkan, K. K., & Holme, I. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.033 · Cited by 122
Bone, H. G., Kiel, D. P., Lindsay, R. S., Lewiecki, E. M., Bolognese, M. A., Leary, E. T., Lowe, W., & McClung, M. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1909 · Cited by 104
Beishuizen, E. D., van de Ree, M. A., Jukema, J. W., Tamsma, J. T., van der Vijver, J. C. M., Meinders, A. E., Putter, H., & Huisman, M. V. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2887 · Cited by 95
Statins: Is It Really Time to Reassess Benefits and Risks?
Goldfine, A. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1203020 · Cited by 87
Idker, P. A. M. R., Ifai, N. A. R., Learfield, M. I. C., Owns, O. R. D., Eis, E., Iles, J. S. H. M., Otto, M., & Orce, A. I. F. (2001) · Cited by 62
Statins, risk assessment, and the new American prevention guidelines
Lloyd‐Jones, D. M., Goff, D. C., & Stone, N. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62348-x · Cited by 61
The west of Scotland Coronary Prevention study: A trial of cholesterol reduction in scottish men
Shepherd, J. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80480-9 · Cited by 58
Newman, C. B., Szarek, M. J., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., DeMicco, D. A., Auster, S. B., & Fuller, J. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.029 · Cited by 49
Albert, M. A., Glynn, R. J., Fonseca, F. A. H., Lorenzatti, A. J., Ferdinand, K. C., MacFadyen, J. G., & Ridker, P. M. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.032 · Cited by 48
Prevention of Cataracts by Statins
Kostis, J. B., & Dobrzynski, J. M. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413511690 · Cited by 42
Statins and newly diagnosed diabetes
Jick, S. S., & Bradbury, B. D. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02142.x · Cited by 36
Gotto, A. M. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2288 · Cited by 21
The Statins in Prevention of Coronary Heart Diseases in Type 2 Diabetics
Heljić, B., Velija-Ašimi, Z., & Kulić, M. (2009) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2009.2860 · Cited by 18
Rockville, F. L. (2015) · Cited by 5
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Patnode, C. D., Evans, C. V., Senger, C. A., Redmond, N., & Lin, J. S. (2017) · JAMA · doi:10.1001/jama.2017.3303 · Cited by 380
The Risks and Benefits of Myopia Control
Bullimore, M. A., Ritchey, E. R., Shah, S., Leveziel, N., Bourne, R. R. A., & Flitcroft, D. I. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.04.032 · Cited by 321
Gencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., Braunwald, E., Giugliano, R. P., & Sabatine, M. S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32332-1 · Cited by 318
Laptook, A. R., Shankaran, S., Tyson, J. E., Munoz, B., Bell, E. F., Goldberg, R. N., Parikh, N. A., Ambalavanan, N., Pedroza, C., Pappas, A., et al. (2017) · JAMA · doi:10.1001/jama.2017.14972 · Cited by 313
Metadata
- Authors
- Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-15
- Volume
- 316
- Issue
- 19
- Pages
- 2008
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2552951299
- Cited by
- 568
- References
- 73
- FWCI
- 55.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.